Dr. Joanna Mitri, the company’s chief medical officer, shared the update in a Product Theater session at ADA today. Mitri said the company plans to launch the automated insulin delivery system on July 7. The company had said as recently as March that it previously expected a second-quarter launch.

Sequel built its twiist system on underlying drug delivery technology developed by DEKA R&D. Dean Kamen, co-founder of Sequel and founder of DEKA, commercialized the first wearable insulin pump for diabetes and last year said the twiist system “represents the next generation of insulin delivery.” Sequel won FDA clearance for the twiist system in March 2024.